Seagen Talks Up 24% Growth, Not About Speculated Merck Buyout
Daiichi Arbitration Is Another Wildcard
The Seattle-based biotech reported a 24% increase in product sales in the second quarter amid speculation that Merck is about to acquire the company.
You may also be interested in...
Less than two year after going public by a SPAC merger, Gemini will reverse merge with hematology-focused Disc. Bristol Myers Squibb and GentiBio will join forces on Treg development for inflammatory bowel disorders.
Keytruda- and Gardasil-driven revenue growth exceeded forecasts and Merck expects to keep the PD-1 blockbuster cash coming with earlier-stage indications and a potential subcutaneous formulation.
Seagen/Astellas announced Phase Ib/II trial data for the combination that could lead to an accelerated approval for the antibody-drug conjugate in first-line bladder cancer.